Sympathetic and immune interactions during dynamic exercise. Mediation via a beta 2-adrenergic-dependent mechanism.
BACKGROUND
The relation between the sympathetic nervous system and the immune system has not been fully defined. Recent investigations have suggested an adrenergically driven efflux of specific beta 2-receptor-rich lymphocyte subsets into the circulation with either exercise or infusion of exogenous catecholamines.


RESULTS
To determine whether acute sympathetic stimulation mediates immunoregulatory cell traffic and function via a beta 2-receptor mechanism, we exercised 20 healthy volunteers before and after 1 week of treatment with either the nonselective beta-antagonist propranolol or the beta 1-selective antagonist metoprolol. Before treatment, exhaustive exercise according to the Bruce protocol led to a marked lymphocytosis. Tsuppressor/cytotoxic (Ts/c) and natural killer cells, subtypes with the largest density of beta-receptors, showed the most pronounced increases after exercise, with less impressive elevations in T(helper) and B cells. With respect to function, exhaustive exercise led to a decrease in concanavalin A-stimulated IL-2 receptor expression and [3H]thymidine incorporation while enhancing natural killer cell activity. One week of propranolol therapy blunted the exercise-induced increases in circulating Ts/c and natural killer subpopulations as well as the previously observed alterations in cellular immune function. Treatment with the beta 1-selective antagonist metoprolol, however, did not impair the influence of exercise on any of the above parameters.


CONCLUSIONS
Acute sympathetic stimulation by exhaustive exercise leads to selective release of immunoregulatory cells into the circulation with subsequent alterations in cellular immune function, either secondary to subset changes or as a result of direct catecholamine effects on function. These changes are attenuated by propranolol but not metoprolol, suggesting a beta 2-mediated mechanism.
Murray
D R
DR
Department of Medicine, University of California San Diego.
Irwin
M
M
Rearden
C A
CA
Ziegler
M
M
Motulsky
H
H
Maisel
A S
AS
D000328:Adult; D002395:Catecholamines / Q000097:blood; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D006801:Humans; D007107:Immune System / Q000502:physiology*; D007694:Killer Cells, Natural / Q000502:physiology; D016131:Lymphocyte Subsets / Q000187:drug effects; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008790:Metoprolol / Q000494:pharmacology; D005082:Physical Exertion; D011433:Propranolol / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000502:physiology*; D013936:Thymidine / Q000493:pharmacokinetics
D002395:Catecholamines; D011943:Receptors, Adrenergic, beta; D015375:Receptors, Interleukin-2; D003208:Concanavalin A; D011433:Propranolol; D008790:Metoprolol; D013936:Thymidine